MedicalResearch.com Interview with:
[caption id="attachment_48814" align="alignleft" width="160"]
Dr. Zarrinpar[/caption]
Amir Zarrinpar, MD, PhD
Assistant Professor, Division of Gastroenterology
University of California, San Diego
MedicalResearch.com: What is the background for this study?
Response: Over the last decade, physicians are beginning to recognize obesity as a disease that requires specific attention; they are more engaged with treating obesity itself rather than its metabolic consequences (such as type 2 diabetes, high blood pressure, cholesterol problems, and/or non-alcoholic fatty liver disease). However, treating obesity is very difficult and many patients don’t succeed in getting the minimum weight loss (approximately 5%) needed to get beneficial health effects. Recent obesity treatment guidelines recommend avoiding placing patients who are obese on obesogenic medication, or medication that have weight gain as a significant side effect.
Despite this recommendation, we noticed many patients who seek treatment for obesity in our clinics are on obesogenic medications. We first noticed that about 40% of patients who are undergoing bariatric surgery at UCSD were prescribed an obesogenic medication. These patients had worse weight loss outcomes compared to patients who did not have any obesogenic medications published that study recently in the International Journal of Obesity.
We wondered whether these findings were specific to bariatric surgery or if patients who were undergoing behavioral treatment (that is, diet and exercise) also had poor weight loss outcomes if they were on obesogenic medications.
Dr. Zarrinpar[/caption]
Amir Zarrinpar, MD, PhD
Assistant Professor, Division of Gastroenterology
University of California, San Diego
MedicalResearch.com: What is the background for this study?
Response: Over the last decade, physicians are beginning to recognize obesity as a disease that requires specific attention; they are more engaged with treating obesity itself rather than its metabolic consequences (such as type 2 diabetes, high blood pressure, cholesterol problems, and/or non-alcoholic fatty liver disease). However, treating obesity is very difficult and many patients don’t succeed in getting the minimum weight loss (approximately 5%) needed to get beneficial health effects. Recent obesity treatment guidelines recommend avoiding placing patients who are obese on obesogenic medication, or medication that have weight gain as a significant side effect.
Despite this recommendation, we noticed many patients who seek treatment for obesity in our clinics are on obesogenic medications. We first noticed that about 40% of patients who are undergoing bariatric surgery at UCSD were prescribed an obesogenic medication. These patients had worse weight loss outcomes compared to patients who did not have any obesogenic medications published that study recently in the International Journal of Obesity.
We wondered whether these findings were specific to bariatric surgery or if patients who were undergoing behavioral treatment (that is, diet and exercise) also had poor weight loss outcomes if they were on obesogenic medications.
Yaakov Hoffman, PhD.
Senior Lecturer and Clinical Psychologist
Interdisciplinary Department of Social Sciences
Max & Anna Webb St. Ramat-Gan, Israel, 5290002
MedicalResearch.com: What is the background for this study?
Foundation: This study was conceptualized during a conversation we had, namely, Dr. Yaakov Hoffman, Interdisciplinary department of social sciences, Bar Ilan University, and Professor Menachem Ben-Ezra School of Social Work, Ariel University, following the release of the Antman movie. We are both psychologists who are also avid Marvel superhero fans. In this meaningful conversation we discussed the issue of fear of insects which led to the idea that positive exposure to phobic stimuli (exposure to spider or ants) within the context of Marvel superheroes will lead to robust reduction in phobic symptoms. As most of the conventional treatments for specific phobias use exposure to the phobic stimuli in neutral contexts, we thought that framing the exposure in a positive fun, albeit fantasy context would yield robust results, as well as perhaps reducing stigma.






Dr. Kendall[/caption]
Dr Kimberley Kendall MBBCh
Wellcome Trust Clinical Research Fellow
[caption id="attachment_48630" align="alignleft" width="150"]
